Immunotherapy success rates for breast cancer vary widely depending on the subtype, stage, and a key biomarker called PD-L1. The strongest results are in triple-negative breast cancer (TNBC), where adding immunotherapy to chemotherapy has pushed pathological complete response rates to nearly 65% in early-stage disease. For other subtypes, the picture is more nuanced, and some breast cancers don’t respond to immunotherapy at all.
Unlike cancers such as melanoma or lung cancer, where immunotherapy has become a cornerstone across the board, breast cancer responds unevenly. Your subtype matters enormously, and so does whether your cancer is caught early or has already spread.
Triple-Negative Breast Cancer: The Strongest Results
TNBC accounts for about 10 to 15% of all breast cancers. It lacks the three most common receptors that other breast cancer treatments target, which historically made it harder to treat. Immunotherapy has changed that picture substantially.
In early-stage TNBC, the landmark KEYNOTE-522 trial tested pembrolizumab (a checkpoint inhibitor) combined with chemotherapy before surgery. Among patients who received the combination, 64.8% achieved a pathological complete response, meaning no cancer was detectable in tissue removed during surgery. Patients who received chemotherapy alone achieved that response 51.2% of the time. That 13.6 percentage point difference translated into meaningful long-term gains: 3-year event-free survival reached 84.5% with immunotherapy versus 76.8% without, and 5-year overall survival was 86.6% compared to 81.7%.
For metastatic TNBC, the numbers are more sobering but still represent progress. In the IMpassion130 trial, patients whose tumors tested positive for PD-L1 had a median overall survival of 25 months when treated with immunotherapy plus chemotherapy, compared to 15.5 months with chemotherapy alone. That’s a gain of nearly 10 months, which was a significant step forward for a cancer that had few effective options beyond standard chemotherapy.
Hormone Receptor-Positive Breast Cancer
Hormone receptor-positive, HER2-negative breast cancer is the most common subtype, making up roughly 70% of cases. It has traditionally been considered “cold” from an immune standpoint, meaning it doesn’t attract much attention from the immune system. Immunotherapy results here are more modest, but emerging data suggests it still helps a subset of patients.
In the KEYNOTE-756 trial, adding pembrolizumab to chemotherapy before surgery improved the pathological complete response rate to 24.3%, up from 15.6% with chemotherapy alone. Those numbers are lower than what’s seen in TNBC, but the improvement is real. An earlier trial, I-SPY2, showed similar trends: a 30% complete response rate with immunotherapy versus 13% without.
In the metastatic setting, one phase 2 trial combined a checkpoint inhibitor with chemotherapy and a drug that blocks blood vessel growth. The objective response rate was 74% in hormone receptor-positive patients, though this was a small study and these results haven’t yet been confirmed in larger trials.
HER2-Positive Breast Cancer
Adding immunotherapy to existing HER2-targeted treatments has not yet shown a clear benefit. In the KATE2 trial, combining a checkpoint inhibitor with an antibody-drug conjugate did not meaningfully improve progression-free survival: 8.2 months with immunotherapy versus 6.8 months without, a difference that was not statistically significant. The combination also caused more side effects.
There was a hint of benefit in patients whose tumors were PD-L1 positive, but this needs further study. For now, HER2-positive breast cancer is primarily treated with highly effective targeted therapies rather than immunotherapy.
Who Qualifies for Immunotherapy
Not every breast cancer patient is eligible. A biomarker called PD-L1 plays a central role in determining whether immunotherapy is likely to help, particularly in metastatic disease. PD-L1 is a protein that some cancer cells produce to hide from the immune system. Labs measure it using a metric called the Combined Positive Score (CPS), which looks at how much PD-L1 is present in tumor tissue.
For metastatic TNBC, the FDA-approved threshold is a CPS of 10 or higher. Patients whose tumors meet this cutoff can receive pembrolizumab in combination with chemotherapy. Below that score, immunotherapy has not shown a reliable survival benefit in metastatic TNBC, though other options such as PARP inhibitors may be relevant for patients with inherited BRCA1 or BRCA2 mutations.
For early-stage TNBC treated before surgery, immunotherapy is approved regardless of PD-L1 status. The KEYNOTE-522 results showed benefit across the broader population, so PD-L1 testing is not required for eligibility in that setting.
Side Effects and Risks
Immunotherapy works by releasing the brakes on your immune system, which means it can sometimes attack healthy tissue along with cancer cells. These immune-related side effects can affect the skin, gut, liver, thyroid, lungs, and other organs.
Across cancer types, about 40% of patients receiving checkpoint inhibitors experience some degree of immune-related side effects. Roughly 20% develop severe (high-grade) reactions that require treatment interruption or additional medications such as steroids. Combination immunotherapy regimens carry higher risks, with severe side effect rates climbing to 55 to 60% in some cancers, though breast cancer typically uses a single checkpoint inhibitor rather than a combination.
Most immune-related side effects are manageable when caught early. Fatigue, skin rashes, and thyroid problems are among the most common. Some effects, particularly thyroid damage, can be permanent and require lifelong medication. Your treatment team will monitor bloodwork regularly to catch problems before they become serious.
How Long Treatment Lasts
There is no universal consensus on the optimal duration of immunotherapy. In early-stage TNBC, the typical approach involves immunotherapy alongside chemotherapy before surgery, followed by continued immunotherapy after surgery for a total treatment period of roughly one year.
For metastatic disease, treatment generally continues for up to two years as long as it’s working and side effects remain tolerable. If the cancer is stable or responding after two years, stopping treatment is sometimes considered. If the cancer later progresses after stopping, restarting immunotherapy is an option.
One of the notable features of immunotherapy is the potential for durable responses. Some patients continue to benefit long after treatment ends, though this applies to only a fraction of those treated. Researchers are still working to identify which patients are most likely to experience these lasting responses.